The DEA telemedicine cliff: what psychiatry and SUD practices must do before December 31, 2026

What changed in September

For more than three years, practitioners have been able to prescribe Schedule II through V controlled medications to patients they have never seen in person, as long as the prescription came out of an audio-video telemedicine encounter. Audio-only was allowed for FDA-approved opioid use disorder medications in Schedules III through V. That authority has been renewed four times. The fourth temporary extension took effect January 1, 2026 and runs through December 31, 2026.

On September 21, 2026, the Office of Information and Regulatory Affairs logged the DEA final rule titled Special Registrations for Telemedicine and Limited State Telemedicine Registrations (RIN 1117-AB40) as received and pending review. The federal regulatory agenda lists final action for November 2026. The text under review is not public, so nobody outside government knows yet how far it moved from the January 2025 proposal.

That leaves psychiatric practices, PMHNP-led groups, opioid treatment programs and office-based buprenorphine programs with one quarter to prepare for a rule they cannot read yet. The work is still worth doing now, because most of it is the same whichever version is published: knowing which patients depend on telemedicine-only prescribing, and which prescribers would need new registrations.

What is already settled: buprenorphine by telemedicine

One piece is no longer temporary. The buprenorphine rule at 21 CFR 1306.51 lets a practitioner prescribe Schedule III through V medications approved for opioid use disorder through a telemedicine encounter, and it names audio-only systems as allowed. The conditions are specific, and each one shows up in the chart.

The practitioner must review the prescription drug monitoring program data for the state where the patient is located, covering the last year, before issuing the prescription, and must record the date and time of that review in the record. Telemedicine-only prescribing is capped at six calendar months from the first prescription. After that, more prescriptions need at least one in-person medical evaluation or another form of telemedicine authority under the Controlled Substances Act. If the PDMP cannot be reached, the prescriber can issue a seven-day supply and has to document the failed attempt, and that supply counts toward the six months.

• PDMP review for the patient's state, documented with date and time, before every telemedicine-only prescription
• A six-month clock per patient that starts on the first prescription date
• In-person evaluation scheduled before month six, or another lawful telemedicine pathway documented
• Prescriptions under this section only for treatment of opioid use disorder

What the proposed special registration would require

The January 2025 proposal is the best available guide to what the final rule will look like, with the caveat that final rules often change after comment. It proposed three special registrations and a separate DEA-issued state telemedicine registration for each state where patients are located. The registrations would run on a three-year cycle.

For behavioral health, the Advanced Telemedicine Prescribing Registration matters most. Under the proposal, psychiatrists, and mid-level practitioners board certified in treating psychiatric disorders, are among the narrow group eligible to prescribe Schedule II medications by telemedicine. A practice that relies on telemedicine-only Schedule II prescribing for ADHD, for example, would be the most exposed if the final rule keeps those limits.

Why the revenue cycle should care

This is a prescribing rule, not a billing rule, but the money follows the patient. If a medication management visit cannot end in a lawful prescription, the patient has to be seen in person or move to another prescriber. Either way, the telehealth visit you bill today may not happen in January. DEA's own extension notice cites a stakeholder summary of 2024 data: of an estimated 44.6 million controlled substance prescriptions across 258 organizations, more than 7 million, about 16 percent, were issued without a prior in-person evaluation.

The same notice points to what happened when Medicare's telehealth flexibilities lapsed on September 30, 2025: fee-for-service telemedicine visits fell 24 percent in the first 17 days. A lapse in prescribing authority would hit psychiatric medication management the same way, and quickly.

The Q4 2026 work list

None of these steps depends on the final text. Each one gives you a list of names, so leadership can see the exposure before January.

• Pull a census of active patients receiving controlled substance prescriptions from telemedicine-only encounters, split by schedule and by the state the patient is located in
• Flag Schedule II patients first and offer in-person evaluations before December 31, since they are the most restricted group under the proposal
• Build the six-month buprenorphine clock into the scheduling system for every OUD patient started by telemedicine
• List each prescriber's DEA registrations and PDMP access by state, and compare it with the patient-location report
• Budget for registration fees and staff time if the final rule follows the proposal
• Keep telehealth claim coding (place of service, modifiers, audio-only flags) separate from the prescribing question, because Medicare telehealth billing rules run on their own timeline
• Draft patient letters now so they can go out the week the rule is published

What we are watching

Three things will decide how hard January lands: whether the final rule is published in time for registrations to be issued before December 31, whether DEA pairs it with a transition period or a fifth extension, and how much of the Schedule II framework survives. We will update this page when the Federal Register publishes the final text.